Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Letter to the Editor
  • Published:

The choice of in-hospital or home administration for plerixafor injection to poor mobilizers has no adverse consequence on subsequent hematopoietic stem cell harvest

Bone Marrow Transplantation volume 52, pages 1212–1214 (2017)Cite this article

Subjects

Significant advances in the outcome of patients with malignant blood diseases took place over the past decades. Although adopting further breakthroughs in medical sciences, clinicians also continue to optimize the delivery of increasingly complex treatment strategies, with growing attention being paid to patients’ quality of life and health care systems sustainability.

For some specific subsets of diseases such as poor-prognosis or relapsed non-Hodgkin lymphomas, Hodgkin diseases or multiple myelomas, the treatment protocol includes high-dose chemotherapy supported with autologous hematopoietic cell transplantation (ASCT). This however can be envisaged only when mobilized PBSC collection and cryopreservation is successful.1

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

References

  1. Mohty M, Duarte RF, Croockewit S, Hubel K, Kvalheim G, Russell N . The role of plerixafor in optimizing peripheral blood stem cell mobilization for autologous stem cell transplantation. Leukemia 2011; 25: 1–6.

    Article  CAS  Google Scholar 

  2. DiPersio JF, Micallef IN, Stiff PJ, Bolwell BJ, Maziarz RT, Jacobsen E et al. Phase III prospective randomized double-blind placebo-controlled trial of plerixafor plus granulocyte colony-stimulating factor compared with placebo plus granulocyte colony-stimulating factor for autologous stem-cell mobilization and transplantation for patients with non-Hodgkin's lymphoma. J Clin Oncol 2009; 27: 4767–4773.

    Article  CAS  Google Scholar 

  3. DiPersio JF, Stadtmauer EA, Nademanee A, Micallef IN, Stiff PJ, Kaufman JL et al. Plerixafor and G-CSF versus placebo and G-CSF to mobilize hematopoietic stem cells for autologous stem cell transplantation in patients with multiple myeloma. Blood 2009; 113: 5720–5726.

    CAS  Google Scholar 

  4. EU SmPC Mozobil. http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/001030/WC500030686.pdf.

  5. Chabannon C, Bijou F, Miclea JM, Milpied N, Grouin JM, Mohty M . A nationwide survey of the use of plerixafor in patients with lymphoid malignancies who mobilize poorly demonstrates the predominant use of the ‘on-demand’ scheme of administration at French autologous hematopoietic stem cell transplant programs. Transfusion 2015; 55: 2149–2157.

    Article  CAS  Google Scholar 

  6. Highlights of prescribing information. Mozobil. Food and Drug Administration Reference ID: 3801700. http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/022311s016lbl.pdf2008.

  7. Liles WC, Broxmeyer HE, Rodger E, Wood B, Hubel K, Cooper S et al. Mobilization of hematopoietic progenitor cells in healthy volunteers by AMD3100, a CXCR4 antagonist. Blood 2003; 102: 2728–2730.

    Article  CAS  Google Scholar 

  8. Liles WC, Rodger E, Broxmeyer HE, Dehner C, Badel K, Calandra G et al. Augmented mobilization and collection of CD34+ hematopoietic cells from normal human volunteers stimulated with granulocyte-colony-stimulating factor by single-dose administration of AMD3100, a CXCR4 antagonist. Transfusion 2005; 45: 295–300.

    Article  CAS  Google Scholar 

  9. Lefrere F, Mauge L, Rea D, Ribeil JA, Dal Cortivo L, Brignier AC et al. A specific time course for mobilization of peripheral blood CD34+ cells after plerixafor injection in very poor mobilizer patients: impact on the timing of the apheresis procedure. Transfusion 2013; 53: 564–569.

    Article  CAS  Google Scholar 

  10. Flomenberg N, Devine SM, Dipersio JF, Liesveld JL, McCarty JM, Rowley SD et al. The use of AMD3100 plus G-CSF for autologous hematopoietic progenitor cell mobilization is superior to G-CSF alone. Blood 2005; 106: 1867–1874.

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Institut Paoli-Calmettes, Centre de Lutte Contre le Cancer, Université d’Aix-Marseille, Inserm CBT 1409, Centre d’Investigations Cliniques en Biothérapie, Marseille, France

    C Chabannon

  2. Institut Bergonié, Bordeaux, France

    F Bijou

  3. Inserm U1219 ‘Population Health’ and Université de Rouen, Rouen, France

    J-M Grouin

  4. Etablissement Français du Sang, Direction Médicale et Scientifique, La Plaine St Denis, France

    P Drillat

  5. Centre Hospitalier et Universitaire de Bordeaux, Bordeaux, France

    N Milpied

  6. Hôpital Saint Antoine, Assistance Publique des Hôpitaux de Paris (AP-HP), Université Pierre et Marie Curie (UPMC), INSERM, UMRs 938, Centre de Recherches Saint-Antoine, Paris, France

    M Mohty

Authors
  1. C Chabannon
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. F Bijou
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. J-M Grouin
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. P Drillat
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. N Milpied
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. M Mohty
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to C Chabannon.

Ethics declarations

Competing interests

All authors have received compensation from SANOFI SA, as members of the scientific advisory board for the OSMOZ registry and study. The OSMOZ registry was promoted by SANOFI SA (grant # MOZ22510). The study was approved by the Comité Economique des Produits de Santé (CEPS); the Direction Générale de la Santé (DGS) approved the composition of the scientific advisory board.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Chabannon, C., Bijou, F., Grouin, JM. et al. The choice of in-hospital or home administration for plerixafor injection to poor mobilizers has no adverse consequence on subsequent hematopoietic stem cell harvest. Bone Marrow Transplant 52, 1212–1214 (2017). https://doi.org/10.1038/bmt.2017.103

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/bmt.2017.103

Search

Advanced search

Quick links